PCM
IGMS

Penserra Capital Management’s IGM Biosciences IGMS Stock Holding History

Penserra Capital Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-585
Closed -$38K – 1441
2021
Q3 		$38K Hold
585
– – ﹤0.01% 1130
2021
Q2 		$48K Buy
585
+10
+2% +$741 ﹤0.01% 1011
2021
Q1 		$44K Buy
575
+20
+4% +$1.82K ﹤0.01% 830
2020
Q4 		$49K Buy
+555
New +$39K ﹤0.01% 690

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Penserra Capital Management's IGMS Position: Q4 2021 in Review

Penserra Capital Management sold out of IGM Biosciences (IGMS) in Q4 2021, closing a stake of 585 shares — an estimated $38K sold.

Penserra Capital Management first reported a position in IGMS in Q4 2020 and held it in 4 quarters. The position peaked at $49K in Q4 2020. 87 funds tracked by Wall St. Rank hold IGMS as of Q4 2021.

  • Penserra Capital Management reported no remaining IGM Biosciences position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 585 IGM Biosciences shares in Q4 2021, an estimated $38K.
  • Penserra Capital Management first reported a position in IGM Biosciences in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's IGM Biosciences position peaked at $49K in Q4 2020.
  • 87 funds tracked by Wall St. Rank held IGM Biosciences as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.